Skip to main content

Table 1 Association between the clinicopathological features of CRC patients stratified by POLE mutation, MSI, and MLH1 methylation status

From: Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations

Characteristics

POLE (n = 4)

MSI-M (n = 29)

MSI-U (n = 36)

non-MSI (n = 944)

P value

Age

Mean (range)

52.5 (41–63)

76.9 (60–89)

59.5 (24–87)

66.0 (21–95)

 < .0001

 

 > 70

0 (0)

22 (75.9)

7 (19.4)

365 (38.7)

 < .0001

 

55–69

2 (50%)

7 (24.1)

18 (50.0)

441 (46.7)

 
 

40–54

2 (50%)

0 (0)

7 (19.4)

118 (12.5)

 
 

 < 39

0 (0)

0 (0)

4 (11.1)

20 (2.1)

 

Gender

Female

2 (50%)

19 (65.5%)

13 (36.1%)

389 (41.2%)

0.0593

 

Male

2 (50%)

10 (34.5%)

23 (63.9%)

555 (58.8%)

 

Tumour location

Right

4 (100%)

27 (93.1%)

13 (36.1%)

282 (29.9%)

 < .0001

 

Left

0 (0)

2 (6.9%)

23 (63.9%)

662 (70.1%)

 

Histology

Well

0 (0)

7 (24.1%)

6 (16.7%)

276 (29.2%)

 < .0001

 

Moderate

3 (75%)

7 (24.1%)

20 (55.6%)

571 (60.5%)

 
 

Poor/muc

1 (25%)

15 (51.7%)

10 (27.8%)

97 (10.3%)

 

UICC stage

I

1 (25%)

11 (37.9%)

14 (38.9%)

197 (20.9%)

0.0011

 

II

3 (75%)

10 (34.5%)

14 (38.9%)

246 (26.1%)

 < .0001*

 

III

0 (0)

6 (20.7%)

4 (11.1%)

297 (31.5%)

 
 

IV

0 (0)

2 (6.9%)

4 (11.1%)

204 (21.6%)

 

RAS mutational status

BRAF mutation

0 (0)

20 (69.0%)

4 (11.1%)

35 (3.7%)

 < .0001

 

KRAS mutation

0 (0)

0 (0)

8 (22.2%)

307 (32.5%)

 
 

Wild-type

4 (100%)

9 (31.0%)

24 (66.7%)

602 (63.8%)

 

Methylation score

Mean (range)

2 (2)

3.2 (2–4)

1.9 (0–4)

1.9 (0–4)

 < .0001

MGMT methylation

Extensive

0 (0)

17 (58.6%)

4 (11.1%)

166 (17.6%)

 < .0001

 

Partial

0 (0)

1 (3.5%)

5 (13.9%)

60 (6.4%)

 
 

Unmethylation

4 (100%)

11 (37.9%)

27 (75.0%)

718 (76.1%)

 

SFRP2 methylation

Extensive

4 (100%)

28 (96.6%)

23 (63.9%)

602 (63.8%)

0.0158

 

Partial

0 (0)

1 (3.5%)

8 (22.2%)

194 (20.6%)

 
 

Unmethylation

0 (0)

0 (0)

5 (13.9%)

148 (15.7%)

 
  1. P-values were calculated using the Chi-squared test
  2. * P-value was calculated between stages I–II and III–IV